Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) – Pipeline Review, H2 2016’, provides in depth analysis on Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted pipeline therapeutics.

The report provides comprehensive information on the Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note:

Certain sections in the report may be removed or altered based on the availability and relevance of data.

Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A)

The report reviews Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

AbbVie Inc

Handok Inc

XBiotech Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) Overview 6

Therapeutics Development 7

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Stage of Development 7

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Therapy Area 8

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Indication 9

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Pipeline Products Glance 10

Late Stage Products 10

Early Stage Products 11

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Products under Development by Companies 12

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Therapeutics Assessment 14

Assessment by Monotherapy/Combination Products 14

Assessment by Mechanism of Action 15

Assessment by Route of Administration 16

Assessment by Molecule Type 18

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Companies Involved in Therapeutics Development 20

AbbVie Inc 20

Handok Inc 21

XBiotech Inc 22

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Drug Profiles 23

ABT-981 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

CV-18C3 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

HL-2351 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Monoclonal Antibodies to Inhibit IL-1a for Myocardial Infarction and Atherosclerosis - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

RA-18C3 - Drug Profile 27

Product Description 27

Mechanism Of Action 27

R&D Progress 27

T-218C3 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

Xilonix - Drug Profile 30

Product Description 30

Mechanism Of Action 30

R&D Progress 30

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Dormant Projects 35

Interleukin 1 Alpha (IL 1 Alpha or Hematopoietin 1 or IL1A) - Featured News & Press Releases 36

Dec 07, 2016: XBiotech Completes Enrollment in Global Phase III Study using Xilonix Monotherapy to Treat Advanced Colorectal Cancer 36

Oct 12, 2016: Xbiotech Announces Successful Completion of EMA GMP Inspection 36

Jul 22, 2016: XBiotech Provides Update on Xilonix Phase III Programs in US and EU 37

Jul 14, 2016: The Debate on the Phase 3 Trial of MABp1 Presented at the 18th ESMO World Congress of Gastrointestinal Cancer 37

Jul 02, 2016: XBiotech Presents Pivotal Phase III Data Showing Xilonix Demonstrated Significant Clinical Response in Advanced Colorectal Cancer Patients Refractory to Further Treatment 39

Jun 08, 2016: Appoints Trey Benson as New Commercial Head to Lead Strategic Commercial Development for the Companys Extensive Product Portfolio 40

May 24, 2016: XBiotech to Present Positive Preliminary Survival Data on Xilonix(TM) at the 18th European Society of Medical Oncology World Congress on Gastrointestinal Cancer 41

Apr 19, 2016: XBiotech to Present Pivotal Phase 3 Data on Xilonix at European Society of Medical Oncology’s World Congress on Gastrointestinal Cancer 41

Apr 04, 2016: European Medicines Agency Grants Accelerated Assessment of Marketing Authorization Application for Xilonix, XBiotech’s True Human Therapeutic Antibody Treatment for Advanced Colorectal Cancer 42

Mar 23, 2016: XBiotech Announces European Medicines Agency Validates Marketing Authorization Application for Xilonix in the Treatment of Advanced Colorectal Cancer 43

Mar 08, 2016: XBiotech Announces Submission of Marketing Authorization Application for Candidate Colorectal Cancer Therapy to European Medicines Agency 43

Mar 04, 2016: European Medicines Agency Grants Eligibility for Submission of XBiotech’s Marketing Authorization Application 44

Mar 02, 2016: XBiotech to Deliver Presentation on Novel Study Design and Phase III Results From European Study on Xilonix During Meeting at the European Parliament 45

Jan 21, 2016: XBiotech to Attend and Present at the ASCO 2016 Gastrointestinal Cancers Symposium 45

Jan 08, 2016: XBiotech Reports Additional Positive Data From Phase III European Trial of Xilonix in Advanced Colorectal Cancer 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Number of Products under Development by Companies, H2 2016 12

Products under Development by Companies, H2 2016 13

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Action, H2 2016 15

Number of Products by Stage and Route of Administration, H2 2016 17

Number of Products by Stage and Molecule Type, H2 2016 19

Pipeline by AbbVie Inc, H2 2016 20

Pipeline by Handok Inc, H2 2016 21

Pipeline by XBiotech Inc, H2 2016 22

Dormant Projects, H2 2016 35

List of Figures

List of Figures

Number of Products under Development for, H2 2016 7

Number of Products under Development by Therapy Area, H2 2016 8

Number of Products under Development by Top 10 Indication, H2 2016 9

Comparative Analysis by Late Stage Development, H2 2016 10

Comparative Analysis by Early Stage Products, H2 2016 11

Assessment by Monotherapy/Combination Products, H2 2016 14

Number of Products by Stage and Mechanism of Actions, H2 2016 15

Number of Products by Routes of Administration, H2 2016 16

Number of Products by Stage and Routes of Administration, H2 2016 16

Number of Products by Molecule Types, H2 2016 18

Number of Products by Stage and Molecule Type, H2 2016 18

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports